drugset

Drugs / TSR-033

Follow last change Feb 2025 re-read 2 minutes ago

TSR-033

also known as encelimab

Monoclonal antibody

Developed for: neoplasm
Investigated by: GlaxoSmithKline · Tesaro, Inc.

Trials 1 · a red edge is where a trial was stopped

today NCT03250832 · Ph 1

201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03250832	Aug 2017 → Jun 2022	neoplasm	Tesaro, Inc.	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02817633 Background	Jul 2016 → Mar 2027 expected	neoplasm	Tesaro, Inc.	Active not recruiting	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	TSR-033	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02817633 ↗ 1 NCT03250832 ↗
Known as	encelimab	“CITRINO, a two-part, Phase 1 dose-escalation study, evaluated encelimab (TSR-033; novel anti-LAG-3) monotherapy and in combination in patients with advanced/metastatic solid tumours.” PMID 40016550 ↗ Feb 2025
Modality	Monoclonal antibody	“TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.” NCT03250832 ↗